<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965442</url>
  </required_header>
  <id_info>
    <org_study_id>Post-mastectomy pain</org_study_id>
    <nct_id>NCT03965442</nct_id>
  </id_info>
  <brief_title>Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome</brief_title>
  <official_title>Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome: a Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Base</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Base</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic postoperative pain is an entity that is usually neglected by anesthetists, but
      several studies show that the choice of anesthetic technique may interfere with this
      prevalence. Esmolol is a selective beta-blocker of ultra fast duration that has been studied
      as a perioperative venous adjuvant with antihyperalgesic and opioid sparing action. The
      investigators ventured the possibility of this anti-hyperalgesic effect attenuating the
      chronic pain syndrome post-mastectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-mastectomy chronic pain syndrome</measure>
    <time_frame>Through study completion, an average of 6 to 9 month</time_frame>
    <description>Incidence analysis using a questionnaire applied to patients in the late postoperative period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the intensity of pain: Pain Scores on the Visual Analog Scale</measure>
    <time_frame>Through study completion, an average of 6 to 9 month</time_frame>
    <description>Pain Scores on the Visual Analog Scale, from zero to 10: 0 being represented by absence of pain and 10 being the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify possible risk factors</measure>
    <time_frame>Through study completion, an average of 6 to 9 month</time_frame>
    <description>Incidence analysis using a questionnaire applied to patients in the late postoperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratify the possible types of pain</measure>
    <time_frame>Through study completion, an average of 6 to 9 month</time_frame>
    <description>Application of a questionnaire to identify the characteristics of pain (Neuropatic or non-neuropatic pain)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Post-mastectomy Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients who underwent mastectomy under standard general anesthesia
Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <description>Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Patients who underwent mastectomy under standard general anesthesia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Patients who underwent mastectomy under general anesthesia with esmolol infusion</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously submitted to the study Analgesic Effect of Intraoperative Esmolol in
        Mastectomies: a randomized placebo controlled trial, will be submitted to a questionnaire
        of adapted from DNS4.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients previously submitted to the study Analgesic Effect of Intraoperative Esmolol in
        Mastectomies: a randomized placebo controlled trial

        Exclusion Criteria:

          -  Patient aged less than 18 years and over 65 years;

          -  Patients who refuse to participate in the study;

          -  Patients with pulmonary disease;

          -  Patients with cardiac, renal or hepatic disease;

          -  Use of psychoactive drug;

          -  Patients with sinus bradycardia;

          -  Pregnant women;

          -  Patients with allergy to dipyrone, morphine;

          -  Patients with chronic pain prior to the surgical procedure;

          -  Patients with neurological disorders;

          -  Patients undergoing surgical resurfacing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabricio T Mendonça, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Base do Distrito Federal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabricio T Mendonça, MD</last_name>
    <phone>+5561981882640</phone>
    <email>correidofabricio@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Base do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70680250</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamil Elias, MD</last_name>
      <phone>556133151588</phone>
      <email>uamphbdf@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Viviane Rezende, MD</last_name>
      <phone>556133151331</phone>
      <email>vrezende@icab.med.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568. Erratum in: JAMA. 2012 Nov 21;308(19):1973.</citation>
    <PMID>19903919</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Base</investigator_affiliation>
    <investigator_full_name>Fabricio Tavares Mendonca</investigator_full_name>
    <investigator_title>Preceptor correspondent for anesthesiology residency</investigator_title>
  </responsible_party>
  <keyword>Post-mastectomy Pain Syndrome</keyword>
  <keyword>Esmolol</keyword>
  <keyword>Perioperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

